Health Condition 1: H32- Chorioretinal disorders in diseases classified elsewhere Health Condition 2: H308- Other chorioretinal inflammations
Conditions
Interventions
Intervention1: Topical interferon eyedrop: IFN eye drops were prepared from commercially available subcutaneous injection IFN 3 MU . The drug was diluted using 2.5ml of sterile water for injection to
Sponsors
Md eye hospitalMLN medical college
Eligibility
Inclusion criteria
Inclusion criteria: • Patients diagnosed with UME or Irvine gass syndrome and advised for intensive topical, systemic, periocular or intraocular injection of steroids or intravitreal injection of anti-VEGF, or increase in immunomodulatory therapy . • Patients already undergoing treatment for UME or P-CME and showing worsening , defined as increase in size and number of cystoid spaces and/or any increase in central macular thickness (CMT) as appreciated on SD-OCT scan after 3-4 weeks of the previous treatment.
Exclusion criteria
Exclusion criteria: 1. Patients with macular edema due to overlapping pathology other than uveitis or Irvine gass syndrome (e.g.diabetic macular edema,ARMD, choroidal neovascularisation,tumour,Central serous retinopathy,retinal vessel occlusion,post pan retinal photocoagulation ,retinitis pigmentosa). 2. Patients with any of the following ocular manifestations at the time of start of treatment- conjunctival hyperaemia,follicular hypertrophy, giant papillary conjunctivitis, irritation , corneal epithelial defect,flu like symptoms,severe dryness. 3. Patients with severe systemic disease or weight loss, deranged CBC,LFT,KFT or any mental disorder. 4. Patients with follow-up of less than one month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Central macular thicknessTimepoint: 2weeks,4weeks,8weeks,12weeks,16weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Vision,intraocular pressureTimepoint: 2weeks,4weeks,8weeks,12weeks,16weeks | — |
Countries
India
Contacts
Public ContactApurva bagla
Md eye hospital
Outcome results
None listed